
  
    
      
        Background_NNP
        Antibody-directed_NNP enzyme_NN prodrug_NN therapy_NN (_( ADEPT_NNP )_) [_NN 1_CD 2_CD 3_CD
        4_CD 5_CD ]_NN is_VBZ one_CD of_IN the_DT promising_JJ new_JJ approaches_NNS that_WDT
        selectively_RB target_NN tumor_NN cells_NNS ,_, thus_RB reducing_VBG toxic_JJ side_NN
        effects_NNS to_TO patients_NNS ._. In_IN this_DT approach_NN ,_, an_DT enzyme_NN is_VBZ
        conjugated_JJ to_TO a_DT tumor-specific_JJ antibody_NN ._. The_DT antibody_NN
        selectively_RB localizes_NNS the_DT enzyme_NN to_TO the_DT tumor_NN cell_NN surface_NN ._.
        Subsequent_JJ administration_NN of_IN a_DT prodrug_NN substrate_NN of_IN the_DT
        enzyme_NN leads_VBZ to_TO the_DT enzyme-catalyzed_JJ release_NN of_IN the_DT free_JJ
        drug_NN at_IN the_DT tumor_NN site_NN ._. This_DT strategy_NN addresses_VBZ the_DT
        stoichiometry_NN ,_, controlled_VBN drug_NN release_NN and_CC poor_JJ antibody_NN
        penetration_NN problems_NNS associated_VBN with_IN the_DT use_NN of_IN monoclonal_NN
        antibody-drug_JJ conjugates_NNS [_NN 6_CD 7_CD 8_CD ]_NN ._. In_IN addition_NN ,_, because_IN
        the_DT process_NN of_IN drug_NN release_NN is_VBZ enzymatic_JJ ,_, a_DT single_JJ enzyme_NN
        can_MD generate_VB a_DT large_JJ amount_NN of_IN free_JJ drug_NN ._. Consequently_RB ,_, a_DT
        small_JJ amount_NN of_IN antibody_NN can_MD be_VB used_VBN to_TO reduce_VB
        immunogenicity_NN ._.
        It_PRP is_VBZ important_JJ that_IN the_DT free_JJ drug_NN in_IN the_DT ADEPT_NNP approach_NN
        be_VB highly_RB toxic_JJ ._. Using_VBG highly_RB toxic_JJ agents_NNS can_MD reduce_VB the_DT
        amount_NN of_IN the_DT monoclonal_NN antibody_NN required_VBD ,_, thereby_RB
        reducing_VBG side_NN effects_NNS ._. CC-_NNP 1065_CD (_( Figure_NN 1_LS )_) is_VBZ among_IN the_DT most_RBS
        potent_JJ antitumor_NN agents_NNS discovered_VBD [_NN 9_CD 10_CD 11_CD 12_CD 13_CD ]_NN ._. It_PRP
        binds_NNS to_TO double-stranded_JJ B-DNA_NNP within_IN the_DT minor_JJ groove_NN with_IN
        a_DT sequence_NN preference_NN for_IN 5_CD '_POS -_: d_SYM (_( A_DT /_NN GNTTA_NNP )_) -_: 3_CD '_POS and_CC
        5_CD '_POS -_: d_SYM (_( AAAAA_NNP )_) -_: 3_CD '_POS ,_, and_CC alkylates_NNS the_DT N_NNP 3_CD position_NN of_IN the_DT
        3_CD '_POS -_: adenine_NN with_IN its_PRP$ left-hand_JJ CPI_NNP segment_NN [_NN 14_CD 15_CD ]_NN ._.
        CC-_NNP 1065_CD also_RB inhibits_NNS gene_NN transcription_NN by_IN interfering_VBG
        with_IN binding_VBG of_IN the_DT TATA_NNP box-binding_JJ protein_NN to_TO its_PRP$ target_NN
        DNA_NNP [_NN 16_CD ]_NN ._. Despite_IN its_PRP$ high_JJ potency_NN and_CC broad_JJ spectrum_NN of_IN
        antitumor_NN activity_NN ,_, CC-_NNP 1065_CD cannot_NN be_VB used_VBN in_IN humans_NNS
        because_IN it_PRP causes_VBZ delayed_VBD death_NN in_IN experimental_JJ animals_NNS [_NN
        17_CD ]_NN ._. To_TO pursue_VB compounds_NNS possessing_VBG the_DT potent_JJ antitumor_NN
        activity_NN but_CC devoid_JJ of_IN the_DT toxic_JJ side_NN effects_NNS of_IN the_DT parent_NN
        compound_NN ,_, many_JJ CC-_NNP 1065_CD analogues_NNS have_VBP been_VBN synthesized_JJ [_NN 18_CD
        19_CD 20_CD 21_CD 22_CD 23_CD 24_CD 25_CD 26_CD ]_NN ._.
        Beta-lactamases_NNP have_VBP been_VBN widely_RB investigated_VBN for_IN their_PRP$
        role_NN in_IN the_DT metabolism_NN of_IN antibiotics_NNS including_VBG
        cephalosporins_NNS and_CC penicillins_NNS ._. Because_IN of_IN the_DT high_JJ
        catalytic_JJ efficiency_NN and_CC broad_JJ substrate_NN specificity_NN ,_,
        β-lactamases_JJ have_VBP been_VBN extensively_RB used_VBN in_IN the_DT ADEPT_NNP
        approach_NN to_TO activate_VBP prodrugs_NNS of_IN vinca_NN alkaloids_NNS [_NN 27_CD ]_NN ,_,
        nitrogen_NN mustard_NN [_NN 28_CD 29_CD 30_CD 31_CD 32_CD ]_NN ,_, doxorubicin_NN [_NN 33_CD 34_CD
        35_CD 36_CD ]_NN and_CC others_NNS [_NN 37_CD ]_NN ._. To_TO take_VB advantage_NN of_IN the_DT potent_JJ
        antitumor_NN activity_NN of_IN the_DT CC-_NNP 1065_CD class_NN of_IN compounds_NNS and_CC
        the_DT ADEPT_NNP approach_NN ,_, we_PRP have_VBP synthesized_JJ β-lactam_JJ prodrugs_NNS ._.
        Herein_NNP ,_, we_PRP report_VBP synthesis_NN and_CC preliminary_JJ cytotoxic_JJ
        effects_NNS of_IN a_DT prodrug_NN comprised_VBN of_IN a_DT cephalosporin_NN and_CC a_DT
        CC-_NNP 1065_CD analogue_NN (_( Figure_NN 1_LS )_) ._.
        Prodrug_NNP 
        2_CD is_VBZ expected_VBN to_TO be_VB less_RBR toxic_JJ than_IN its_PRP$
        corresponding_JJ free_JJ drug_NN 
        1_CD ._. However_RB ,_, it_PRP is_VBZ expected_VBN that_IN the_DT
        prodrug_NN will_MD be_VB converted_VBN to_TO the_DT potent_JJ free_JJ drug_NN by_IN
        β-lactamases_JJ localized_JJ on_IN the_DT tumor_NN cell_NN surface_NN by_IN an_DT
        antibody_NN (_( Figure_NN 2_LS )_) ._. This_DT selective_JJ activation_NN of_IN prodrug_NN 
        2_CD at_IN the_DT tumor_NN site_NN will_MD lead_VB to_TO
        enhanced_JJ antitumor_NN therapeutic_JJ efficacy_NN ._.
      
      
        Results_NNS and_CC discussion_NN
        Prodrug_NNP 
        2_CD was_VBD synthesized_JJ as_IN shown_VBN in_IN Figure_NN 3_CD ._.
        The_DT key_JJ intermediate_JJ ,_, 
        7_CD ,_, was_VBD made_VBN using_VBG methods_NNS developed_VBN by_IN
        Jungheim_NNP et_CC al_NN ._. [_NN 33_CD ]_NN ,_, and_CC Rodrigues_NNP ,_, et_CC al_NN ._. [_NN 35_CD 36_CD ]_NN
        with_IN modifications_NNS ._. The_DT spectra_NN data_NN including_VBG NMR_NNP and_CC MS_NNP
        of_IN compounds_NNS 
        4_CD -_: 7_CD were_VBD identical_JJ to_TO those_DT as_IN
        reported_VBN ._. Compound_NN 
        1_CD was_VBD treated_VBN with_IN 
        7_CD in_IN DMF_NNP to_TO afford_VB the_DT protected_VBN
        prodrug_NN 
        8_CD ._. Removal_NNP of_IN the_DT t-butyl_JJ protection_NN
        group_NN from_IN 
        8_CD generated_VBD the_DT targeted_VBN prodrug_NN 
        2_CD with_IN good_JJ yield_NN ._.
        The_DT cytotoxicity_NN of_IN prodrug_NN 
        2_CD and_CC its_PRP$ corresponding_JJ free_JJ drug_NN 
        1_CD was_VBD tested_VBN against_IN U_NNP 937_CD leukemia_NN
        cells_NNS ,_, and_CC the_DT results_NNS are_VBP presented_VBN in_IN Table_NNP 1_CD ._. When_WRB the_DT
        drugs_NNS were_VBD incubated_JJ with_IN U_NNP 937_CD cells_NNS for_IN a_DT period_NN of_IN 48_CD -_: h_NN ,_,
        prodrug_NN 
        2_CD (_( IC_NNP 
        50_CD :_: 0_CD ._. 9_CD nM_NN )_) is_VBZ 10_CD -_: fold_VB less_RBR toxic_JJ than_IN
        its_PRP$ corresponding_JJ free_JJ drug_NN 
        1_CD (_( IC_NNP 
        50_CD :_: 0_CD ._. 09_CD nM_NN )_) ._. As_IN observed_VBD for_IN other_JJ
        compounds_NNS of_IN the_DT CC-_NNP 1065_CD class_NN [_NN 25_CD 37_CD 38_CD ]_NN ,_, both_DT prodrug_NN 
        2_CD and_CC the_DT free_JJ drug_NN 
        1_CD caused_VBN DNA_NNP fragmentation_NN ,_, and_CC the_DT
        cells_NNS died_VBN by_IN apoptosis_NNS (_( data_NNS not_RB shown_VBN )_) ._.
      
      
        Conclusion_NNP
        This_DT is_VBZ the_DT first_JJ report_NN demonstrating_VBG synthesis_NN of_IN a_DT
        prodrug_NN comprised_VBN of_IN a_DT cephalosporin_NN and_CC a_DT CC-_NNP 1065_CD
        analogue_NN ._. The_DT preliminary_JJ in_IN vitro_NN studies_NNS show_VBP the_DT prodrug_NN
        to_TO be_VB less_RBR toxic_JJ than_IN the_DT free_JJ drug_NN ._. Due_JJ to_TO the_DT slow_JJ
        non-enzymatic_JJ degradation_NN of_IN the_DT cephalosporins_NNS in_IN solution_NN
        [_NN 39_CD ]_NN ,_, the_DT ratio_NN of_IN toxicity_NN of_IN cephalosporin-containing_JJ
        prodrugs_NNS to_TO their_PRP$ corresponding_JJ free_JJ drugs_NNS is_VBZ generally_RB not_RB
        very_RB high_JJ ._. However_RB ,_, some_DT of_IN the_DT prodrugs_NNS are_VBP very_RB effective_JJ
        against_IN tumors_NNS in_IN mouse_NN models_NNS ._. For_IN example_NN ,_, a_DT
        cephalosporin-doxorubicin_JJ prodrug_NN was_VBD 9_CD -_: fold_VB less_RBR toxic_JJ
        than_IN free_JJ doxrubicin_NN against_IN tumor_NN cells_NNS in_IN vitro_NN ,_, but_CC
        caused_VBD tumor_NN regression_NN when_WRB tested_VBN in_IN tumor_NN xenograft_NN
        models_NNS [_NN 40_CD ]_NN ._. A_DT cephalosporin-vinca_JJ alkaloid_NN prodrug_NN was_VBD
        5_CD -_: fold_VB less_RBR toxic_JJ than_IN the_DT free_JJ drug_NN against_IN tumor_NN cells_NNS in_IN
        vitro_NN ,_, but_CC was_VBD highly_RB effective_JJ in_IN tumor_NN xenograft_NN models_NNS
        in_IN vivo_NN [_NN 41_CD ]_NN ._. When_WRB taxol_NN was_VBD conjugated_JJ to_TO a_DT
        cephalosporin_NN ,_, the_DT resulting_VBG prodrug_NN was_VBD approximately_RB
        10_CD -_: fold_VB less_RBR toxic_JJ than_IN free_JJ taxol_NN against_IN tumor_NN cells_NNS in_IN
        vitro_NN [_NN 36_CD ]_NN ._. Thus_RB ,_, prodrug_NN 
        2_CD has_VBZ the_DT potential_NN to_TO be_VB useful_JJ in_IN
        cancer_NN treatment_NN using_VBG the_DT ADEPT_NNP approach_NN ._. We_PRP will_MD report_VB
        more_RBR biological_JJ data_NNS in_IN due_JJ course_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        Cephalothin_NNP sodium_NN ,_, 
        3_CD ,_, (_( 2_CD ._. 5_LS g_SYM ,_, 5_CD ._. 98_CD mmol_NN )_) was_VBD suspended_VBN in_IN
        dichloromethane_NN (_( 150_CD mL_NN )_) ._. Anhydrous_NNP hydrogen_NN chloride_NN (_( 4_CD N_NNP
        in_IN dioxane_NN ,_, 2_CD mL_NN ,_, 8_CD mmol_NN )_) was_VBD added_VBN ,_, and_CC the_DT reaction_NN
        mixture_NN was_VBD stirred_VBD for_IN 30_CD min_NN at_IN room_NN temperature_NN ._. 
        tert_NN -_: Butyl_NNP trichloroacetimidate_NN (_( 3_CD ._. 2_LS
        mL_NN ,_, 17_CD ._. 84_CD mmol_NN )_) was_VBD added_VBN ,_, and_CC the_DT reaction_NN mixture_NN was_VBD
        stirred_VBD overnight_JJ at_IN room_NN temperature_NN ._. The_DT reaction_NN mixture_NN
        was_VBD washed_VBN consecutively_RB with_IN water_NN (_( 150_CD mL_NN )_) ,_, saturated_VBD
        sodium_NN hydrogen_NN carbonate_NN solution_NN (_( 150_CD mL_NN )_) and_CC water_NN (_( 150_CD
        mL_NN )_) ._. The_DT organic_JJ solution_NN was_VBD dried_VBN using_VBG sodium_NN sulfate_NN ._.
        The_DT solvent_JJ was_VBD removed_VBN ,_, and_CC the_DT product_NN was_VBD purified_JJ by_IN
        flash_VBP column_NN chromatography_NN eluting_VBG with_IN a_DT solvent_JJ
        consisting_VBG of_IN dichloromethane_NN ,_, ethyl_NN acetate_NN and_CC hexane_NN
        (_( 1_CD /_NN 1_CD /_NN 3_CD ,_, v_NN /_NN v_NN )_) affording_VBG 1_CD ._. 2_CD g_SYM of_IN 
        4_CD (_( 44_CD %_NN yield_NN )_) ._.
        Compound_NN 
        4_CD (_( 1_CD g_SYM ,_, 2_CD ._. 21_CD mmol_NN )_) was_VBD dissolved_VBN in_IN
        methanol_NN (_( 70_CD mL_NN )_) ,_, and_CC solid_JJ potassium_NN carbonate_NN (_( 120_CD mg_NN )_)
        was_VBD added_VBN ._. The_DT mixture_NN was_VBD stirred_VBD for_IN 2_CD h_NN at_IN room_NN
        temperature_NN ,_, and_CC acetic_JJ acid_NN (_( 200_CD μL_NN )_) was_VBD added_VBN to_TO quench_NN
        the_DT reaction_NN ._. The_DT solvent_JJ was_VBD removed_VBN ,_, and_CC the_DT product_NN was_VBD
        purified_JJ by_IN flash_VBP column_NN chromatography_NN eluting_VBG with_IN 8_CD %_NN
        acetone_NN in_IN dichloromethane_NN to_TO afford_VB 220_CD mg_NN of_IN 
        5_CD (_( 24_CD %_NN yield_NN )_) ._.
        Compound_NN 
        5_CD (_( 280_CD mg_NN ,_, 0_CD ._. 68_CD mmol_NN )_) was_VBD dissolved_VBN in_IN
        anhydrous_JJ THF_NNP (_( 40_CD mL_NN )_) ,_, and_CC dimethylaminopyridine_NN (_( 1_CD mg_NN )_) ,_,
        p-nitrophenylchloroformate_JJ (_( 0_CD ._. 2_LS g_SYM ,_, 1_CD mmol_NN )_) and_CC 2_CD ,_,
        6_CD -_: lutidine_NN (_( 120_CD μL_NN )_) ,_, 1_CD mmol_NN )_) were_VBD added_VBN sequentially_RB ._. The_DT
        reaction_NN mixture_NN was_VBD stirred_VBD overnight_JJ at_IN room_NN temperature_NN ._.
        The_DT solvent_JJ was_VBD removed_VBN ,_, and_CC the_DT product_NN was_VBD purified_JJ by_IN
        flash_VBP column_NN chromatography_NN eluting_VBG with_IN 5_CD %_NN ethyl_NN acetate_NN
        in_IN dichloromethane_NN to_TO afford_VB 271_CD mg_NN of_IN 
        6_CD (_( 69_CD %_NN yield_NN )_) ._.
        To_TO a_DT solution_NN of_IN 
        6_CD (_( 50_CD mg_NN ,_, 87_CD μmol_NN )_) in_IN dichloromethane_NN
        (_( 2_CD mL_NN )_) cooled_VBN to_TO 0_CD °_NN C_NNP was_VBD added_VBN 
        m-_NN chloroperoxybenzoic_JJ acid_NN (_( CPBA_NNP ,_, 26_CD
        mg_NN ,_, 93_CD μmol_NN )_) in_IN 0_CD ._. 5_CD mL_NN of_IN dichloromethane_NN ._. The_DT reaction_NN
        mixture_NN was_VBD stirred_VBD for_IN 15_CD min_NN at_IN 0_CD °_NN C_NNP ,_, and_CC was_VBD then_RB washed_VBN
        with_IN 5_CD %_NN potassium_NN hydrogen_NN carbonate_NN solution_NN followed_VBN by_IN
        brine_NN ._. The_DT solvent_JJ was_VBD removed_VBN ,_, and_CC the_DT product_NN was_VBD
        purified_JJ by_IN flash_VBP column_NN chromatography_NN eluting_VBG with_IN 8_CD %_NN
        ethyl_NN acetate_NN in_IN dichloromethane_NN to_TO afford_VB 34_CD mg_NN of_IN 
        7_CD (_( 66_CD %_NN yield_NN )_) ._.
        Compound_NN 
        7_CD (_( 15_CD mg_NN ,_, 25_CD μmol_NN )_) was_VBD added_VBN to_TO a_DT
        solution_NN of_IN 
        1_CD (_( 9_CD mg_NN ,_, 23_CD μmol_NN )_) in_IN DMF_NNP (_( 0_CD ._. 3_LS mL_NN )_) ,_,
        which_WDT was_VBD synthesized_JJ as_IN we_PRP reported_VBD previously_RB [_NN 20_CD ]_NN ,_,
        and_CC the_DT reaction_NN mixture_NN was_VBD stirred_VBD overnight_JJ at_IN room_NN
        temperature_NN ._. The_DT product_NN was_VBD purified_JJ by_IN thin_JJ layer_NN
        chromatography_NN eluting_VBG with_IN ethyl_NN acetate_NN and_CC hexane_NN (_( 3_CD /_NN 1_CD ,_,
        v_NN /_NN v_NN )_) to_TO afford_VB 12_CD mg_NN of_IN 
        8_CD (_( 62_CD %_NN yield_NN )_) ._. 1_LS H_NNP NMR_NNP (_( DMF-d_NNP 
        7_CD ,_, ppm_NN )_) :_: 10_CD ._. 70_CD (_( s_VBZ ,_, 1_CD H_NNP )_) ,_, 9_CD ._. 15_CD (_( s_VBZ ,_, 1_CD H_NNP )_) ,_,
        8_CD ._. 63_CD (_( s_VBZ ,_, 1_CD H_NNP )_) ,_, 8_CD ._. 25_CD -_: 7_CD ._. 85_CD (_( m_NN ,_, 4_CD H_NNP )_) ,_, 7_CD ._. 60_CD -_: 7_CD ._. 19_CD (_( m_NN ,_, 7_CD H_NNP )_) ,_,
        7_CD ._. 05_CD -_: 6_CD ._. 95_CD (_( m_NN ,_, 2_CD H_NNP )_) ,_, 6_CD ._. 05_CD -_: 6_CD ._. 01_CD (_( m_NN ,_, 1_CD H_NNP )_) ,_, 5_CD ._. 39_CD -_: 5_CD ._. 30_CD (_( d_SYM ,_, 1_CD H_NNP )_) ,_,
        5_CD ._. 12_CD -_: 4_CD ._. 79_CD (_( m_NN ,_, 5_CD H_NNP )_) ,_, 4_CD ._. 35_CD -_: 4_CD ._. 27_CD (_( m_NN ,_, 1_CD H_NNP )_) ,_, 4_CD ._. 19_CD -_: 3_CD ._. 75_CD (_( m_NN ,_, 6_CD H_NNP )_) ,_,
        1_CD ._. 58_CD (_( s_VBZ ,_, 9_CD H_NNP )_) ._. FAB_NNP MS_NNP 
        m_NN /_NN e_SYM 866_CD ._. 0_CD (_( M_NNP +_NN Na_NNP )_) +_NN ._.
        To_TO a_DT solution_NN of_IN 
        8_CD (_( 5_CD mg_NN ,_, 5_CD ._. 9_CD μmol_NN )_) in_IN DMF_NNP (_( 0_CD ._. 2_LS mL_NN )_) and_CC
        dichloromethane_NN (_( 1_CD mL_NN )_) was_VBD added_VBN trifluroacetic_JJ acid_NN (_( 1_CD
        mL_NN )_) ,_, and_CC the_DT solution_NN was_VBD stirred_VBD for_IN 2_CD h_NN at_IN room_NN
        temperature_NN ._. The_DT solvent_JJ was_VBD removed_VBN ,_, and_CC ethyl_NN ether_NN was_VBD
        added_VBN ._. The_DT solid_RB was_VBD filtered_VBN ,_, and_CC washed_VBD with_IN ether_NN to_TO
        afford_VB prodrug_NN 
        2_CD (_( 3_CD ._. 7_CD mg_NN ,_, 79_CD %_NN yield_NN )_) ._. 1_LS H_NNP NMR_NNP (_( DMF-d_NNP 
        7_CD ,_, ppm_NN )_) :_: 11_CD ._. 56_CD (_( s_VBZ ,_, 1_CD H_NNP )_) ,_, 10_CD ._. 50_CD (_( s_VBZ ,_, 1_CD
        H_NNP )_) ,_, 9_CD ._. 65_CD (_( s_VBZ ,_, 1_CD H_NNP )_) ,_, 8_CD ._. 25_CD -_: 7_CD ._. 85_CD (_( m_NN ,_, 4_CD H_NNP )_) ,_, 7_CD ._. 60_CD -_: 7_CD ._. 24_CD (_( m_NN ,_, 7_CD H_NNP )_) ,_,
        7_CD ._. 10_CD -_: 6_CD ._. 96_CD (_( m_NN ,_, 2_CD H_NNP )_) ,_, 6_CD ._. 10_CD -_: 6_CD ._. 01_CD (_( m_NN ,_, 1_CD H_NNP )_) ,_, 5_CD ._. 42_CD -_: 5_CD ._. 38_CD (_( d_SYM ,_, 1_CD H_NNP )_) ,_,
        5_CD ._. 10_CD -_: 4_CD ._. 60_CD (_( m_NN ,_, 5_CD H_NNP )_) ,_, 4_CD ._. 35_CD -_: 4_CD ._. 25_CD (_( m_NN ,_, 1_CD H_NNP )_) ,_, 4_CD ._. 20_CD -_: 3_CD ._. 75_CD (_( m_NN ,_, 6_CD H_NNP )_) ._.
        FAB_NNP MS_NNP 
        m_NN /_NN e_SYM 787_CD ._. 1_LS ._.
      
    
  
